Sandoz Appealing Ruling Over Amgen's Enbrel Biosimilar
By Mark Payne · March 13, 2026, 5:20 PM EDT
Sandoz Inc. is appealing after a Virginia federal court ruled it should have brought claims accusing Amgen of blocking competition for the Enbrel biosimilar in a previous patent dispute, according to...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login